Currently, there are 7.48M common shares owned by the public and among those 3.73M shares have been available to trade.
The company’s stock has a 5-day price change of 21.54% and -36.81% over the past three months. DTIL shares are trading 49.61% year to date (YTD), with the 12-month market performance down to -56.64% lower. It has a 12-month low price of $3.61 and touched a high of $19.43 over the same period. DTIL has an average intraday trading volume of 126.76K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 19.40%, -10.42%, and -39.81% respectively.
Institutional ownership of Precision Biosciences Inc (NASDAQ: DTIL) shares accounts for 81.17% of the company’s 7.48M shares outstanding.
It has a market capitalization of $44.98M and a beta (3y monthly) value of 1.47. The stock’s trailing 12-month PE ratio is 111.55, while the earnings-per-share (ttm) stands at $0.05. Price movements for the stock have been influenced by the stock’s volatility, which stands at 14.74% over the week and 12.60% over the month.
Analysts forecast that Precision Biosciences Inc (DTIL) will achieve an EPS of -2.94 for the current quarter, -0.39 for the next quarter and -8.62 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -3.12 while analysts give the company a high EPS estimate of -3.12. Earnings per share for the fiscal year are expected to increase by 100.42%, and -10503.70% over the next financial year.
Looking at the support for the DTIL, a number of firms have released research notes about the stock. BMO Capital Markets stated their Outperform rating for the stock in a research note on January 10, 2025, with the firm’s price target at $34. Guggenheim coverage for the Precision Biosciences Inc (DTIL) stock in a research note released on April 30, 2024 offered a Buy rating with a price target of $19. BTIG Research on their part issued Buy rating on July 27, 2020.
